Application Note: WB: 0.03-0.1μg/ml. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
Calculated MW: 43
Positive Control: The peptide used to generate this antibody is available for purchase (GTX89104-PEP).
Specificity/Sensitivity: This antibody is expected to recognize both reported isoforms (NP_004506.2; NP_001254738.1).
Form: Liquid
Buffer (with preservative): TBS, 0.5% BSA, 0.02% Sodium azide.
Concentration: 0.50 mg/ml (Please refer to the vial label for the specific concentration.)
Background: The protein encoded by this gene is a transcription factor required for T-cell expression of the interleukin 2 gene. It also binds RNA and is an essential component for encapsidation and protein priming of hepatitis B viral polymerase. The encoded 45 kDa protein (NF45, ILF2) forms a complex with the 90 kDa interleukin enhancer-binding factor 3 (NF90, ILF3), and this complex has been shown to affect the redistribution of nuclear mRNA to the cytoplasm, to repair DNA breaks by nonhomologous end joining, and to negatively regulate the microRNA processing pathway. Knockdown of NF45 or NF90 protein retards cell growth, possibly by inhibition of mRNA stabilization. Alternative splicing results in multiple transcript variants. Related pseudogenes have been found on chromosomes 3 and 14. [provided by RefSeq, Dec 2014]
Uniprot ID: Q12905
Antigen Species: Human
Immunogen: Peptide with sequence C-EKAYEKPPEKKEG, from the internal region (near the C Terminus) of the protein sequence according to NP_004506.2; NP_001254738.1.
Purification: Purified by ammonium sulphate precipitation followed by antigen affinity chromatography
Conjugation: Unconjugated
Full Name: interleukin enhancer binding factor 2
Deutsch
English
